| WHO COVID-19 Research Database Your browser doesn't support javascript. Main content 1 2 Footer 3 +A A -A High contrast WHO COVID-19 Research Database العربية 中文 (中国) english français Русский español português News/Update/Help Advanced Show: 20 | 50 | 100 Results 1 - 20 de 707.839 Filter Add filters Full text Database Main subject Type of study Topics Clinical aspect Language Year Document Type Journal Filter Full text (573118) Database MEDLINE (311435) Scopus (60452) Web of Science (48342) EuropePMC (47159) ProQuest Central (40505) EMBASE (37468) medRxiv (19064) ICTRP (16670) WHO COVID (14292) Grey literature (11817) Show more... Main subject COVID-19 (131467) Coronavirus Infections (36980) Pneumonia, Viral (35918) Pandemics (28793) SARS-CoV-2 (24981) Betacoronavirus (16150) COVID-19 Vaccines (6489) Telemedicine (4773) Antiviral Agents (3747) Neoplasms (2708) Show more... Type of study Prognostic study (156401) Risk factors (130322) Randomized controlled trials (118662) Observational study (66054) Diagnostic study (62826) Qualitative research (50517) Etiology study (48462) Clinical Practice Guide (45613) Controlled clinical trial (33146) Reviews (31717) Show more... Topics Vaccines (82075) Long Covid (54950) Variants (29469) Traditional medicine (7683) Language English (623803) Spanish (15159) Chinese (6627) German (6561) Portuguese (6268) French (5817) Indonesian (4720) Russian (4078) Japanese (1697) Italian (1497) Show more... Journal PLoS One (4608) BMJ (3983) Sustainability (3771) Cureus (2597) Sci Rep (2499) American Journal of Respiratory and Critical Care Medicine (2264) Front Public Health (2180) BMJ Open (2039) J Med Virol (1912) Reactions Weekly (1869) Show more... Year 2021 (309397) 2022 (204073) 2020 (190819) 2023 (418) 2019 (69) Document Type Article (609095) Preprint (70712) Clinical Trial Register (16670) Non-conventional (11333) Audio (10) Year range 5 years 10 years Filter 1. Use of Simulation to Visualize Healthcare Worker Exposure to Aerosol in the Operating Room. Frauenfelder, Claire; Hall, Andrew; Walsh, Bill; Ross, Alasdair; Broughton, Emma; Hynds, Robert E; Nandi, Reema; O'Callaghan, Christopher; Butler, Colin R. Simul Healthc ; 17(1): 66-67, 2022 Feb 01. Article | MEDLINE | ID: covidwho-2042677 ABSTRACT SUMMARY STATEMENT: Simulation resources offer an opportunity to highlight aerosol dispersion within the operating room environment. We demonstrate our methodology with a supporting video that can offer operating room teams support in their practical understanding of aerosol exposure and the importance of personal protective equipment. Subject s Operating Rooms , Personal Protective Equipment , Aerosols , Health Personnel , Humans 2. Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2021 ASCRS member survey. Chang, David F; Rhee, Douglas J. J Cataract Refract Surg ; 48(1): 3-7, 2022 Jan 01. Article in English | MEDLINE | ID: covidwho-2042649 ABSTRACT In an online survey of >1200 global cataract surgeons, 66% were using intracameral (IC) antibiotic prophylaxis. This compared with 50% and 30% in the 2014 and 2007 surveys, respectively. Irrigation bottle infusion and intravitreal injection was each used by only 5% of respondents. For IC antibiotics, vancomycin was used by 6% in the United States (52% in 2014), compared with 83% for moxifloxacin (31% in 2014). Equal numbers used compounded moxifloxacin or the Vigamox bottle as the source. There was a decrease in respondents using preoperative (73% from 85%) and postoperative (86% from 97%) topical antibiotic prophylaxis; the latter was not used by 24% of surgeons injecting IC antibiotics. Reasons cited by those not using IC antibiotics include mixing/compounding risk (66%) and being unconvinced of the need (48%). However, 80% believe having a commercially approved IC antibiotic is important; if reasonably priced, this would increase adoption of IC prophylaxis to 93%. Subject s Cataract Extraction , Cataract , Endophthalmitis , Eye Infections, Bacterial , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Endophthalmitis/drug therapy , Endophthalmitis/prevention & control , Eye Infections, Bacterial/drug therapy , Eye Infections, Bacterial/prevention & control , Humans , Postoperative Complications/drug therapy , Postoperative Complications/prevention & control , Surveys and Questionnaires 3. Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients. Morgan, John A; Biggio, Joseph R; Martin, Jane K; Mussarat, Naiha; Chawla, Harsheen K; Puri, Priya; Williams, Frank B. Obstet Gynecol ; 139(1): 107-109, 2022 01 01. Article in English | MEDLINE | ID: covidwho-2042642 Subject s COVID-19/epidemiology , Pandemics , Pregnancy Complications, Infectious/epidemiology , Prenatal Care , SARS-CoV-2 , Adult , COVID-19/etiology , COVID-19/prevention & control , COVID-19 Vaccines/administration & dosage , Cohort Studies , Female , Humans , Pregnancy , Pregnancy Complications, Infectious/etiology , Pregnancy Complications, Infectious/prevention & control , Pregnancy Outcome , Retrospective Studies , Risk Factors , United States/epidemiology 4. Protocols and risks: when less is more. Pannu, Jaspreet; Sandbrink, Jonas B; Watson, Matthew; Palmer, Megan J; Relman, David A. Nat Protoc ; 17(1): 1-2, 2022 01. Article in English | MEDLINE | ID: covidwho-2042330 Subject s Risk Assessment 5. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Huober, Jens; Barrios, Carlos H; Niikura, Naoki; Jarzab, Michal; Chang, Yuan-Ching; Huggins-Puhalla, Shannon L; Pedrini, José; Zhukova, Lyudmila; Graupner, Vilma; Eiger, Daniel; Henschel, Volkmar; Gochitashvili, Nino; Lambertini, Chiara; Restuccia, Eleonora; Zhang, Hong. J Clin Oncol ; : JCO2102772, 2022 Jun 28. Article | MEDLINE | ID: covidwho-2043160 ABSTRACT PURPOSE: Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients. METHODS: Patients with a primary tumor of > 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0) were randomly assigned 1:1 to atezolizumab/placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel, and PH. After surgery, patients were to continue atezolizumab/placebo and PH (total: 1 year of HER2-targeted therapy); those with residual disease could switch to ado-trastuzumab emtansine with atezolizumab/placebo. Coprimary efficacy end points were pathologic complete response (pCR; ypT0/is ypN0) rates in intention-to-treat (ITT) and programmed cell death-ligand 1 (PD-L1)-positive populations. RESULTS: At clinical cutoff (February 5, 2021), pCR rates in the placebo and atezolizumab groups in the ITT populations were 62.7% (n = 143/228) and 62.4% (n = 141/226), respectively (difference -0.33%; 95% CI, -9.2 to 8.6; P = .9551). The pCR rates in the placebo and atezolizumab groups in patients with PD-L1-positive tumors were 72.5% (n = 79/109) and 64.2% (n = 70/109), respectively (difference -8.26%; 95% CI, -20.6 to 4.0; P = .1846). Grade 3-4 and serious adverse events were more frequent in the atezolizumab versus placebo group. Five grade 5 adverse events occurred (four neoadjuvant, one adjuvant; two assigned to study treatment), all with atezolizumab. Overall, the safety profile was consistent with that of atezolizumab in other combination studies. CONCLUSION: Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide-paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1-positive populations. PH and chemotherapy remains standard of care; longer follow-up may help to inform the long-term impact of atezolizumab. 6. COVID-19 follow-up programs across Europe: an ERS END-COVID CRC survey. Valenzuela, Claudia; Nigro, Mattia; Chalmers, James D; Wagers, Scott; Avinash, Aujayeb; Hellemons, Merel E; Löffler-Ragg, Judith; Brightling, Christopher E; Aliberti, Stefano. Eur Respir J ; 2022 Jul 21. Article in English | MEDLINE | ID: covidwho-2043103 7. Older Adults' Resilience Against Impact of Lifestyle Changes During the COVID-19 Pandemic. Kasuga, Ayaka; Yasumoto, Saori; Nakagawa, Takeshi; Ishioka, Yoshiko; Kikuchi, Akari; Inagaki, Hiroki; Ogawa, Madoka; Hori, Noriko; Masui, Yukie; Choe, Hwang; Muto, Hiroyuki; Kabayama, Mai; Godai, Kayo; Ikebe, Kazunori; Kamide, Kei; Ishizaki, Tatsuro; Gondo, Yasuyuki. Gerontol Geriatr Med ; 8: 23337214221116226, 2022. Article in English | MEDLINE | ID: covidwho-2043089 ABSTRACT Background: Older adults were expected to experience a decline in physical activities and an increase in social isolation during the COVID-19 pandemic. Methods: We investigated the changes in living conditions of 508 older adults (79.70 years ± 0.88) before (from July to December 2019) and during (in August 2020) the pandemic. We compared the mean score for the same individual instrumental activities of daily living (IADL), frequency of going out, exercise, and social interaction at two-time points. We also examined the influence of living arrangement (living alone or not) on the frequency of exercise and social interaction. Results: The frequency of going out decreased during the pandemic (in 2020); however, there was no significant change in IADL. The frequency of exercise and social interaction increased irrespective of the living arrangement. The frequency of exercise increased more in those living alone. Conclusions: Although older adults refrained from going out, they compensated for the risks of inactivity in daily life by increasing or maintaining their frequency of exercise and social interactions. The view that "older adults have a poor ability to accommodate the lifestyle changes during the COVID-19 pandemic" may be a stereotypical assumption. 8. Reply to: SARS-CoV-2 mRNA Vaccine Antibody Response in Asthma Patients with Biologic Therapy after Second and Booster Dose: A Real-world Analysis. Runnstrom, Martin C; Lee, F Eun-Hyung. Am J Respir Crit Care Med ; 2022 May 25. Article in English | MEDLINE | ID: covidwho-2042904 9. Reply to: Remote 6-minute Walk Testing in Patients with Pulmonary Hypertension: Further Validation Needed? LaPatra, Tess; Baird, Grayson L; Goodman, Randi; Pinder, Diane; Gaffney, Maeve; Klinger, James R; Palevsky, Harold I; Fritz, Jason; Mullin, Christopher J; Mazurek, Jeremy A; Kawut, Steven M; Ventetuolo, Corey E. Am J Respir Crit Care Med ; 2022 May 24. Article in English | MEDLINE | ID: covidwho-2042903 10. AI for Population and Global Health in Radiology. Anazodo, Udunna C; Adewole, Maruf; Dako, Farouk. Radiol Artif Intell ; 4(4): e220107, 2022 Jul. Article in English | MEDLINE | ID: covidwho-2042889 11. Eroding norms over release of self-spreading viruses. Lentzos, Filippa; Rybicki, Edward P; Engelhard, Margret; Paterson, Pauline; Sandholtz, Wayne Arthur; Reeves, R Guy. Science ; 375(6576): 31-33, 2022 Jan 07. Article in English | MEDLINE | ID: covidwho-2042845 ABSTRACT Risky research on lab-modified self-spreading viruses has yet to present credible paths to upsides. Subject s Animals, Wild , Organisms, Genetically Modified , Pest Control, Biological , Vaccines, Attenuated , Viral Vaccines , Viruses , Animals , Evolution, Molecular , Humans , International Cooperation , Policy , Virus Physiological Phenomena , Viruses/genetics 12. Novel aspects of Raman spectroscopy in skin research. Lunter, Dominique; Klang, Victoria; Kocsis, Dorottya; Varga-Medveczky, Zsófia; Berkó, Szilvia; Erdo, Franciska. Exp Dermatol ; 2022 Jul 15. Article in English | MEDLINE | ID: covidwho-2042832 ABSTRACT The analytical technology of Raman spectroscopy has an almost 100-year history. During this period, many modifications and developments happened in the method like discovery of laser, improvements in optical elements and sensitivity of spectrometer and also more advanced light detection systems. Many types of the innovative techniques appeared (e.g. Transmittance Raman spectroscopy, Coherent Raman Scattering microscopy, Surface-Enhanced Raman scattering and Confocal Raman spectroscopy/microscopy). This review article gives a short description about these different Raman techniques and their possible applications. Then, a short statistical part is coming about the appearance of Raman spectroscopy in the scientific literature from the beginnings to these days. The third part of the paper shows the main application options of the technique (especially confocal Raman spectroscopy) in skin research, including skin composition analysis, drug penetration monitoring and analysis, diagnostic utilizations in dermatology and cosmeto-scientific applications. At the end, the possible role of artificial intelligence in Raman data analysis and the regulatory aspect of these techniques in dermatology are briefly summarized. For the future of Raman Spectroscopy, increasing clinical relevance and in vivo applications can be predicted with spreading of non-destructive methods and appearance with the most advanced instruments with rapid analysis time. 13. A rapid access clinic for psoriasis: first experiences. Reid, Claire; Welsh, Charlotte; Martin-Smith, Holly; Dharmaprasad, Soney; Warren, Richard B; Cordingley, Lis; Griffiths, Christopher E M. Br J Dermatol ; 2022 Mar 15. Article in English | MEDLINE | ID: covidwho-2042830 14. Identification and characterization of virus-encoded circular RNAs in host cells. Chen, Shuting; Zheng, Jie; Zhang, Bingyue; Tang, Xinyue; Cun, Yewei; Wu, Tao; Xu, Yue; Ma, Ting; Cheng, Jingxin; Yu, Zuoren; Wang, Haiyun. Microb Genom ; 8(6)2022 06. Article in English | MEDLINE | ID: covidwho-2042679 ABSTRACT Emerging evidence has identified viral circular RNAs (circRNAs) in human cells infected by viruses, interfering with the immune system and inducing diseases including human cancer. However, the biogenesis and regulatory mechanisms of virus-encoded circRNAs in host cells remain unknown. In this study, we used the circRNA detection tool CIRI2 to systematically determine the virus-encoded circRNAs in virus-infected cancer cell lines and cancer patients, by analysing RNA-Seq datasets derived from RNase R-treated samples. Based on the thousands of viral circRNAs we identified, the biological characteristics and potential roles of viral circRNAs in regulating host cell function were determined. In addition, we developed a Viral-circRNA Database (http://www.hywanglab.cn/vcRNAdb/), which is open to all users to search, browse and download information on circRNAs encoded by viruses upon infection. Subject s RNA, Circular , Viruses , Cell Line , Humans , RNA/genetics , RNA/metabolism , RNA, Circular/genetics , Viruses/genetics 15. Tracheostomy Practices and Outcomes in Children During Respiratory Extracorporeal Membrane Oxygenation. Kohne, Joseph G; MacLaren, Graeme; Rider, Erica; Carr, Benjamin D; Mallory, Palen; Gebremariam, Acham; Friedman, Matthew L; Barbaro, Ryan P. Pediatr Crit Care Med ; 23(4): 268-276, 2022 04 01. Article in English | MEDLINE | ID: covidwho-2042669 ABSTRACT OBJECTIVES: Children receiving prolonged extracorporeal membrane oxygenation (ECMO) support may benefit from tracheostomy during ECMO by facilitating rehabilitation; however, the procedure carries risks, especially hemorrhagic complications. Knowledge of tracheostomy practices and outcomes of ECMO-supported children who undergo tracheostomy on ECMO may inform decision-making. DESIGN: Retrospective cohort study. SETTING: ECMO centers contributing to the Extracorporeal Life Support Organization registry. PATIENTS: Children from birth to 18 years who received ECMO support for greater than or equal to 7 days for respiratory failure from January 1, 2015, to December 31, 2019. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Three thousand six hundred eighty-five children received at least 7 days of ECMO support for respiratory failure. The median duration of ECMO support was 13.0 days (interquartile range [IQR], 9.3-19.9 d), and inhospital mortality was 38.7% (1,426/3,685). A tracheostomy was placed during ECMO support in 94/3,685 (2.6%). Of those who received a tracheostomy on ECMO, the procedure was performed at a median 13.2 days (IQR, 6.3-25.9 d) after initiation of ECMO. Surgical site bleeding was documented in 26% of children who received a tracheostomy (12% after tracheostomy placement). Among children who received a tracheostomy, the median duration of ECMO support was 24.2 days (IQR, 13.0-58.7 d); inhospital mortality was 30/94 (32%). Those that received a tracheostomy before 14 days on ECMO were older (median age, 15.8 yr [IQR, 4.7-15.5] vs 11.7 yr [IQR, 11.5-17.3 yr]; p =0.002) and more likely to have been supported on venovenous-ECMO (84% vs 52%; p = 0.001). Twenty-two percent (11/50) of those who received a tracheostomy before 14 days died in the hospital, compared with 19/44 (43%) of those who received a tracheostomy at 14 days or later (p = 0.03). CONCLUSIONS: Tracheostomies during ECMO were uncommon in children. One in four patients who received a tracheostomy on ECMO had surgical site bleeding. Children who had tracheostomies placed after 14 days were younger and had worse outcomes, potentially representing tracheostomy as a "secondary" strategy for prolonged ECMO support. Subject s Extracorporeal Membrane Oxygenation , Respiratory Insufficiency , Adolescent , Child , Extracorporeal Membrane Oxygenation/methods , Hemorrhage/etiology , Humans , Respiration, Artificial/adverse effects , Retrospective Studies , Tracheostomy/adverse effects , Tracheostomy/methods 16. Public interest in cardiac arrest and cardiopulmonary resuscitation: a Google Trends analysis of the global online search traffic. Birkun, Alexei; Baldi, Enrico; Böttiger, Bernd W. Eur J Emerg Med ; 2022 Jun 09. Article in English | MEDLINE | ID: covidwho-2042665 17. Dermatopathology Trainee World Cup Abstracts Presented at the 25th Virtual Joint Meeting of the International Society of Dermatopathology, May 16-20, 2022. Am J Dermatopathol ; 44(Suppl 1): S17-S19, 2022 Sep 01. Article in English | MEDLINE | ID: covidwho-2042646 18. Poster Abstracts Presented at the 25th Virtual Joint Meeting of the International Society of Dermatopathology, May 16-20, 2022. Am J Dermatopathol ; 44(Suppl 1): S5-S16, 2022 Sep 01. Article in English | MEDLINE | ID: covidwho-2042645 19. Poster Abstracts Presented at the 25th Virtual Joint Meeting of the International Society of Dermatopathology, May 16-20, 2022. Am J Dermatopathol ; 44(Suppl 1): S5-S16, 2022 Sep 01. Article in English | MEDLINE | ID: covidwho-2042644 20. A Decade of GigaScience: Women in Science: Past, Present, and Future. Liu, Lijun; Jovic, Dragomirka; Goodman, Laurie. Gigascience ; 112022 Jun 29. Article in English | MEDLINE | ID: covidwho-2042578 ABSTRACT Over the last decade, women have made decisive advances in increasing equality in science, technology, engineering, and medicine (STEM), but they still do not rival that of men. Many mechanisms to reduce gender discrimination have been addressed; however, little to nothing has been done to tackle the differences in the amount of time women spend on responsibilities at home. This has never been more apparent than during the COVID-19 pandemic. After a decade of advances promoting women, the last two years have seen these advances halted, and the long-term implications for women in STEM will be substantial. Moving forward, career advancement and funding mechanisms need to be adjusted to not just help women catch up, but to become a permanent support mechanism for women in the workplace. The higher amount of responsibilities at home and lack of support for women is not reserved for times of international upheaval: it has just become more apparent. Subject s COVID-19 , Pandemics , COVID-19/epidemiology , Engineering , Female , Humans , Male , Sexism , Technology See more details SEND TO Email Export Print RSS XML SELECTION OF CITATIONS List items (0) Clear list SEARCH DETAIL Consulta Detalhada × (instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados")) Fechar Email × Your name Your email Send to Subject Comments Send result Export × Export format Export This page Selected references (0) All references (limit 50.000) RSS × View RSS Add RSS to My VHL Print × This page Selected references (0)